StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research note issued to investors on Friday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Lipocine Stock Performance
NASDAQ LPCN opened at $5.27 on Friday. The firm has a 50-day moving average of $4.48 and a 200-day moving average of $3.47. Lipocine has a 52-week low of $2.31 and a 52-week high of $7.15.
Lipocine (NASDAQ:LPCN – Get Free Report) last posted its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.11. The company had revenue of $0.22 million for the quarter. As a group, sell-side analysts expect that Lipocine will post -1.49 earnings per share for the current year.
Hedge Funds Weigh In On Lipocine
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
See Also
- Five stocks we like better than Lipocine
- Stock Market Sectors: What Are They and How Many Are There?
- Comprehensive Analysis of PayPal Stock
- ETF Screener: Uses and Step-by-Step Guide
- Intuitive Surgical Stock Can Trend Much Higher This Year
- The Most Important Warren Buffett Stock for Investors: His Own
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.